Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,998 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.
Pett SL, Amin J, Horban A, Andrade-Villanueva J, Losso M, Porteiro N, Sierra Madero J, Belloso W, Tu E, Silk D, Kelleher A, Harrigan R, Clark A, Sugiura W, Wolff M, Gill J, Gatell J, Fisher M, Clarke A, Ruxrungtham K, Prazuck T, Kaiser R, Woolley I, Arnaiz JA, Cooper D, Rockstroh JK, Mallon P, Emery S; Maraviroc Switch (MARCH) Study Group. Pett SL, et al. Among authors: clark a. Clin Infect Dis. 2016 Jul 1;63(1):122-32. doi: 10.1093/cid/ciw207. Epub 2016 Apr 5. Clin Infect Dis. 2016. PMID: 27048747 Free PMC article. Clinical Trial.
Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1.
Giaquinto C, Mawela MP, Chokephaibulkit K, Negra MD, Mitha IH, Fourie J, Fang A, van der Ryst E, Valluri SR, Vourvahis M, Zhang-Roper RY, Craig C, McFadyen L, Clark A, Heera J. Giaquinto C, et al. Among authors: clark a. Pediatr Infect Dis J. 2018 May;37(5):459-465. doi: 10.1097/INF.0000000000001808. Pediatr Infect Dis J. 2018. PMID: 29023357 Free PMC article.
Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment.
Stellbrink HJ, Le Fevre E, Carr A, Saag MS, Mukwaya G, Nozza S, Valluri SR, Vourvahis M, Rinehart AR, McFadyen L, Fichtenbaum C, Clark A, Craig C, Fang AF, Heera J. Stellbrink HJ, et al. Among authors: clark a. AIDS. 2016 May 15;30(8):1229-38. doi: 10.1097/QAD.0000000000001058. AIDS. 2016. PMID: 26854810 Free PMC article. Clinical Trial.
Towards a Maraviroc long-acting injectable nanoformulation.
Tatham LM, Savage AC, Dwyer A, Siccardi M, Scott T, Vourvahis M, Clark A, Rannard SP, Owen A. Tatham LM, et al. Among authors: clark a. Eur J Pharm Biopharm. 2019 May;138:92-98. doi: 10.1016/j.ejpb.2018.04.009. Epub 2018 Apr 21. Eur J Pharm Biopharm. 2019. PMID: 29684534
No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV-1-Infected Subjects.
Vourvahis M, McFadyen L, Nepal S, Valluri SR, Fang A, Fate GD, Wood LS, Marshall JC, Chan PLS, Nedderman A, Haynes J, Savage ME, Clark A, Smith KY, Heera J. Vourvahis M, et al. Among authors: clark a. J Clin Pharmacol. 2019 Jan;59(1):139-152. doi: 10.1002/jcph.1306. Epub 2018 Sep 7. J Clin Pharmacol. 2019. PMID: 30192390 Free PMC article. Clinical Trial.
Prevalence and Outcomes for Heavily Treatment-Experienced Individuals Living With Human Immunodeficiency Virus in a European Cohort.
Pelchen-Matthews A, Borges ÁH, Reekie J, Rasmussen LD, Wiese L, Weber J, Pradier C, Degen O, Paredes R, Tau L, Flamholc L, Gottfredsson M, Kowalska J, Jablonowska E, Mozer-Lisewska I, Radoi R, Vasylyev M, Kuznetsova A, Begovac J, Svedhem V, Clark A, Cozzi-Lepri A; EuroSIDA study. Pelchen-Matthews A, et al. Among authors: clark a. J Acquir Immune Defic Syndr. 2021 Jun 1;87(2):806-817. doi: 10.1097/QAI.0000000000002635. J Acquir Immune Defic Syndr. 2021. PMID: 33587506
Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies.
Walmsley S, Smith DE, Górgolas M, Cahn PE, Lutz T, Lacombe K, Kumar PN, Wynne B, Grove R, Bontempo G, Moodley R, Okoli C, Kisare M, Jones B, Clark A, Ait-Khaled M. Walmsley S, et al. Among authors: clark a. AIDS Res Ther. 2024 Mar 21;21(1):17. doi: 10.1186/s12981-024-00604-9. AIDS Res Ther. 2024. PMID: 38515183 Free PMC article.
Clinical relevance of CYP3A5 genotype on maraviroc exposures.
Vourvahis M, McFadyen L, Heera J, Clark A. Vourvahis M, et al. Among authors: clark a. Drug Metab Dispos. 2015 May;43(5):771-2. doi: 10.1124/dmd.115.063321. Drug Metab Dispos. 2015. PMID: 25838402 Free PMC article. No abstract available.
Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1.
Gartland M, Cahn P, DeJesus E, Diaz RS, Grossberg R, Kozal M, Kumar P, Molina JM, Mendo Urbina F, Wang M, Du F, Chabria S, Clark A, Garside L, Krystal M, Mannino F, Pierce A, Ackerman P, Lataillade M. Gartland M, et al. Among authors: clark a. Antimicrob Agents Chemother. 2022 Jun 21;66(6):e0175121. doi: 10.1128/aac.01751-21. Epub 2022 May 3. Antimicrob Agents Chemother. 2022. PMID: 35502922 Free PMC article. Clinical Trial.
7,998 results